Home » Vertex’s CF Combo Treatment Shows Some Potential
Vertex’s CF Combo Treatment Shows Some Potential
Interim results from a Phase II study show the combination of Vertex Pharmaceuticals’ VX-770 and VX-809 met primary endpoints in treating the defective protein that causes cystic fibrosis (CF) but still may be disappointing in the short-term, an analyst says.
Clinical Trials Advisor
Clinical Trials Advisor
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May